(HEPATOLOGY

2013) Until recently the role of systemic therapy in the management of hepatocellular carcinoma (HCC) was minimal. This changed with the publication of the landmark SHARP study in 2008, which resulted in sorafenib becoming the standard of care option for disease that is not amenable to surgery, ablation, or chemoembolization.1 Although it is true that the median survival advantage in this study was 3 months, its major importance arguably lay in the momentum that it gave to PS-341 research buy the field, and in particular to the development of so-called “antiangiogenic” therapies in HCC. However, antiangiogenic therapies carry their own particular risk profile—including

bleeding, hypertension, proteinuria, and thrombotic events—and this profile has been further and better defined in the time since the first major study demonstrated proof of Apitolisib clinical trial principle for their efficacy.2 In any HCC clinical trial the majority of patients will have underlying cirrhosis and this serves as an additional comorbidity that must be accounted for in the eligibility criteria and risk assessment. It also increases the baseline risk for a patient entering a study, with a greater potential for overlap between the cirrhosis-related risk and the toxicities of the agent under study. Of particular concern is the risk of bleeding in this patient population, who frequently suffer from portal hypertension and thrombocytopenia. However, there are no standardized eligibility criteria across HCC studies—as regards, for example, acceptable platelet count and coagulation parameters or mandated endoscopy to detect varices—to

safeguard against this added risk of bleeding while at the same time taking into account the fact that HCC patients have baseline parameters that would ordinarily be exclusionary. We sought to investigate fully the incidence and relative risk of bleeding events in patients with HCC who have been treated with an antiangiogenic agent, mainly sorafenib, as part of a clinical trial. Our major Etomidate aim was to ascertain whether in fact the bleeding risk is increased in this patient population being treated with this class of drug. Because the majority of randomized studies in HCC have evaluated sorafenib, the greater part of our analysis pertained to this drug. To separate disease-specific factors from potential drug class effect we compared the risk of bleeding in HCC studies with that of randomized studies also evaluating sorafenib in renal carcinoma (RCC). We also set out to describe the considerable heterogeneity that exists with regard to the eligibility criteria for study entry in HCC.